JPRN-jRCTs031260251 Nivolumab Advanced Gastric Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines JPRN-jRCTs031260251—A Single-Arm Phase II Study of Nivolumab plus Trifluridine/Tipiracil as Third-Line or Later Therapy for Unresectable Advanced or Recurrent Gastric Adenocarcinoma or Esophagogastric Junction Adenocarcinoma in Patients without Prior Anti-PD-1 Antibody Treatment. (ANTIEqUE Study:WJOG21525G) (ANTIEqUE Study)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why JPRN-jRCTs031260251 is a hot trial to watch

Advanced Gastric Adenocarcinoma is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. JPRN-jRCTs031260251 is notable because it evaluates Nivolumab in a Phase 2 design while 病勢コントロール率 serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Non-Randomized, masking is Open Label, and the intervention model is Single Group Assignment. Planned enrollment of 33 participants across Japan shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: 病勢コントロール率
• Primary: Disease Control Rate
• Secondary: Overall Survival, Progression-Free Survival,Objective Response Rate, Incidence of Adverse Events
• Secondary: 全生存期間、無増悪生存期間 、奏効割合、有害事象発生割合

Benchmark readouts in the surrounding field

• Neoadjuvant serplulimab plus nab-paclitaxel and SOX in locally advanced gastric or gastroesophageal junction adenocarcinoma: An interim analysis of a multicenter, randomized, double-blind, phase II trial. (Phase 2): pCR = 3.6 % ; pCR = 30.4 %
• Neoadjuvant adebrelimab plus SOX and nab-paclitaxel in resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase II trial. (Phase 2): ORR = 54.55 %
• Updated results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trial. (Phase 2): ORR = 83.8 % ( 68 - 93.8)

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Nivolumab (Approved; PD-1); Trifluridine (Approved; DNA-directed DNA polymerase); Tipiracil Hydrochloride (Pending; TYMP)

Company & Deal Intelligence context: Not reported

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

JPRN-jRCTs031260251 is a focused lens on Advanced Gastric Adenocarcinoma development. Its value will be determined by whether Nivolumab can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.